Descovy and Truvada each have a boxed warning system in their respective product labels regarding the risk of acute exacerbation of hepatitis B after treatment; The Truvada label also carries a warning boxed for the risk of drug resistance with PrEP in case of previous undiagnosed HIV infection. See below for important security information and full information. For more information about Gilead Sciences, please visit the company`s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. This press release contains forward-looking statements, under the Private Securities Litigation Reform Act of 1995, which are subject to risks, uncertainties and other factors, including the risk that the FDA and other regulators may not be able to authorize Descovy for PrEP on time, and all marketing authorizations, if granted, may be subject to significant restrictions on its use. As a result, Descovy will never be able to be successfully marketed for PrEP. These risks, uncertainties and other factors could result in actual results being significantly different from those mentioned in the forward-looking statements. Readers are cautioned not to rely on these forward-looking statements. These and other risks are detailed in Gilead`s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 and submitted to the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead undertakes no commitment to update these forward-looking statements.
In addition to the donation, Gilead`s commitment to the fight against the HIV/AIDS epidemic includes the COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) initiative ™. COMPASS is a 10-year-old girl who is committing US$100 million to fight the HIV/AIDS epidemic in the South through capacity building, mental health and trauma care, as well as awareness and anti-stigma education to combat the HIV/AIDS epidemic in the South. Gilead has patient assistance programs in the United States to help people who need funding to access Truvada for PrEP. For those eligible for commercial insurance, Gilead offers copay coupon support, which allows patients to pay as little as $0 per bottle for Truvada for PrEP. People without insurance can use truvada for PrEP for free through our long-standing medical assistance program or, in the near future, through the new CDC-Gilead partnership. Those interested in learning more about the support programs available to them are encouraged to visit Gilead Advancing Access®`s website at www.gileadadvancingaccess.com. U.S. full Prescribing Information for Descovy and Truvada, including BOXED WARNING, is available under www.gilead.com Important U.S.